Synergistic effects of combined BET and FAK inhibition against Vestibular Schwannomas in NF2-related Schwannomatosis
- 29 August 2024
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 43 (40) , 2995-3002
Abstract
Neurofibromatosis type 2 (NF2) is a rare disorder that causes vestibular schwannomas (VS), meningiomas and ependymomas. To date, there is no FDA approved drug-based treatment for NF2. We have previously identified that BET inhibition can selectively reduce growth of the NF2-null schwannoma and Schwann cells in vitro and tumorigenesis in vivo and, separately, reported that inhibition of Focal Adhesion Kinase 1 (FAK1) via crizotinib has antiproliferative effects in NF2-null Schwann cells. The current study was aimed at determining whether combined BET and FAK inhibition can synergize and to identify the mechanisms of action. A panel of normal and NF2-null Schwann and schwannoma cell lines were used to characterize the effects of combined BET and FAK inhibition in vitro and in vivo using pharmacological and genetic approaches. The mechanism of action was explored by chromatin immunoprecipitation, ChIP-PCR, western blotting, and functional approaches. We find that combined BET and FAK inhibition are synergistic and inhibit the proliferation of NF2-null schwannoma and Schwann cell lines in vitro and in vivo, by arresting cells in the G1/S and G2/M phases of the cell cycle. Further, we identify the mechanism of action through the downregulation of FAK1 transcription by BET inhibition, which potentiates inhibition of FAK by 100-fold. Our findings suggest that combined targeting of BET and FAK1 may offer a potential therapeutic option for the treatment of NF2-related schwannomas.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS117926)
This publication has 27 references indexed in Scilit:
- Insights into recent findings and clinical application of YAP and TAZ in cancerNature Reviews Cancer, 2023
- Targeted Therapies in the Treatment of Vestibular Schwannomas: Current State and New HorizonsOtolaryngologic Clinics of North America, 2023
- A Systematic Review of Recent and Ongoing Clinical Trials in Patients With the NeurofibromatosesPediatric Neurology, 2022
- Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendationGenetics in Medicine, 2022
- BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathwaysCellular Oncology, 2020
- SynergyFinder: a web application for analyzing drug combination dose–response matrix dataBioinformatics, 2020
- Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4Nature Medicine, 2018
- Molecular insights into NF2/Merlin tumor suppressor functionFEBS Letters, 2014
- FRAX597, a Small Molecule Inhibitor of the p21-activated Kinases, Inhibits Tumorigenesis of Neurofibromatosis Type 2 (NF2)-associated SchwannomasJournal of Biological Chemistry, 2013
- Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAKOncogene, 2006